Literature DB >> 14751410

The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.

Szabolcs Szilágyi1, Piero Pollesello, Jouko Levijoki, Petri Kaheinen, Heimo Haikala, István Edes, Zoltán Papp.   

Abstract

The concentration dependences of the Ca(2+)-sensitizing and the phosphodiesterase-inhibitory effects of levosimendan (the (-) enantiomer of [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]propanedinitrile) and its active metabolite, OR-1896 (the (-) enantiomer of N-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl] acetamide), were compared with their positive inotropic effects to reveal their mechanisms of action in guinea pig hearts. In Langendorff-perfused hearts, left ventricular +dP/dt(max) increased by 26+/-4% and 25+/-3% (mean+/-S.E.M.), with EC(50) values of 15+/-2 and 25+/-1 nM for levosimendan and OR-1896, respectively. In permeabilized myocyte-sized preparations, levosimendan and OR-1896 both increased isometric force production via Ca(2+) sensitization (at pCa 6.2), by 51+/-7% and 52+/-6%, with EC(50) values of 8+/-1 and 36+/-7 nM (P<0.05), respectively. Thus, the two molecules could be defined as Ca(2+) sensitizers and positive inotropes with very similar concentration dependences. However, major differences appeared when the phosphodiesterase-inhibitory effects of levosimendan and OR-1896 were probed on the two phosphodiesterase isoforms (phosphodiesterases III and IV) dominant in the left ventricular cardiac tissue. Levosimendan was a 40-fold more potent and a 3-fold more selective phosphodiesterase III inhibitor (IC(50) for phosphodiesterase III=2.5 nM, and IC(50) for phosphodiesterase IV=25 microM, selectivity factor approximately 10000) than OR-1896 (IC(50) for phosphodiesterase III=94 nM, and IC(50) for phosphodiesterase IV=286 microM, selectivity factor approximately 3000). Hence, our data support the hypothesis that levosimendan and OR-1896 both exert positive inotropy via a Ca(2+)-sensitizing mechanism and not via simultaneous inhibition of the phosphodiesterases III and IV isozymes in the myocardium at their maximal free plasma concentrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14751410     DOI: 10.1016/j.ejphar.2003.12.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  29 in total

1.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

Review 2.  Targeting the sarcomere to correct muscle function.

Authors:  Peter M Hwang; Brian D Sykes
Journal:  Nat Rev Drug Discov       Date:  2015-04-17       Impact factor: 84.694

3.  Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.

Authors:  Tsuyoshi Hayashi; Maxime Jean; Huachao Huang; Sydney Simpson; Netty G Santoso; Jian Zhu
Journal:  Antiviral Res       Date:  2017-08-24       Impact factor: 5.970

4.  Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.

Authors:  Timothy A Lewis; Luc de Waal; Xiaoyun Wu; Willmen Youngsaye; Antje Wengner; Charlotte Kopitz; Martin Lange; Stefan Gradl; Manuel Ellermann; Philip Lienau; Stuart L Schreiber; Heidi Greulich; Matthew Meyerson
Journal:  ACS Med Chem Lett       Date:  2019-10-18       Impact factor: 4.345

5.  The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force production in isolated cardiomyocytes and skeletal muscle fibres of the rat.

Authors:  L Nagy; Á Kovács; B Bódi; E T Pásztor; G Á Fülöp; A Tóth; I Édes; Z Papp
Journal:  Br J Pharmacol       Date:  2015-08-04       Impact factor: 8.739

6.  Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Authors:  Ildikó Gödény; Piero Pollesello; István Edes; Zoltán Papp; Zsolt Bagi
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

7.  Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.

Authors:  O Orstavik; S H Ata; J Riise; C P Dahl; G Ø Andersen; F O Levy; T Skomedal; J-B Osnes; E Qvigstad
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 8.  Structures reveal details of small molecule binding to cardiac troponin.

Authors:  Fangze Cai; Monica X Li; Sandra E Pineda-Sanabria; Shorena Gelozia; Steffen Lindert; Frederick West; Brian D Sykes; Peter M Hwang
Journal:  J Mol Cell Cardiol       Date:  2016-11-05       Impact factor: 5.000

Review 9.  Clinical pharmacology of levosimendan.

Authors:  Saila Antila; Stig Sundberg; Lasse A Lehtonen
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts.

Authors:  Z Papp; J Van Der Velden; A Borbély; I Edes; G J M Stienen
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.